Category: Press Coverage

In a move that we hope will lead to faster development of therapies targeting Sarm1 in neurodegenerative diseases, Eli Lilly bought Disarm Therapeutics, the company cofounded by Aaron and Jeff. The Source has a nice write-up covering the Disarm’s founding and acquisition.

We are pleased to have our recent paper looking at the role of TRPV1 in preconditioning the regeneration of DRG neurons reviewed as a “Featured Finding” by eNeuro.